Recurrence-Free Survival Longer With Nivolumab Than Ipilimumab in Melanoma

TUESDAY, Oct. 21, 2025 (HealthDay News) -- For patients with resected stage IIIB-C or stage IV melanoma, recurrence-free survival is longer with nivolumab than